Geisinger, Merck collaborate for patient adherence

Jeff Byers | | Health Exec | Policy & Regulations
Geisinger Health System and pharmaceutical company Merck will enter into a new multi-year collaboration designed to improve patient health outcomes by focusing on shared decision making between patients and physicians and improved patient adherence.

Teams from Danville, Pa.-based Geisinger and Whitehouse Station, N.J.-based Merck will work together to improve patient adherence, increase the role of patients in making decisions to help manage their conditions, share information among extended care teams and improve clinical care processes, according to a statement from the organizations.

The first tool being developed is an interactive web application designed to help primary care clinicians assess and engage patients at risk for cardiometabolic syndrome, a clustering of various risk factors that puts an individual at risk of developing type 2 diabetes and cardiovascular disease.

The web application and other care management tools Merck and Geisinger develop will initially be tested within the Geisinger system, they added. 

Jeff Byers

Related Content

Report: UnitedHealth under investigation by DOJ for Medicare Advantage upcoding
FDA approves first therapy for very rare lipid storage disorder
FDA announces Class I recall of Boston Scientific pacemakers—replacement may be necessary
FDA ends semaglutide shortage, closing the door on compounded Wegovy, Ozempic
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues
Federal judge sides with FTC; case against PBMs to move forward

Around the web

Cardiovascular Business
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Cardiovascular Business
Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Cardiovascular Business
FDA announces new recall of Johnson & Johnson heart pumps over safety concerns

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”